I was referring to the the PillCam Colon 2, which contributed $1.8 million to Given’s total sales of $178 million in 2011. The stock will get a bump if Colon 2 is FDA-approved in the U.S, but it has a long way to go after being so badly beaten down. Shamir is only giving a projection--it's not written in stone. Right now, I'm kicking myself for not selling GIVN when I had a nice profit instead of a hefty loss.